129 related articles for article (PubMed ID: 9733272)
1. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients.
Al-Rawithi S; El-Yazigi A; Ernst P; Al-Fiar F; Nicholls PJ
Bone Marrow Transplant; 1998 Sep; 22(5):485-90. PubMed ID: 9733272
[TBL] [Abstract][Full Text] [Related]
2. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation.
Fasola G; Lo Greco P; Calori E; Zilli M; Verlicchi F; Motta MR; Ricci P; Baccarani M; Tura S
Haematologica; 1991; 76(2):120-5. PubMed ID: 1937169
[TBL] [Abstract][Full Text] [Related]
4. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
6. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.
Kim SY; Lee JW; Lim J; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Kim CC
Biol Blood Marrow Transplant; 2007 Jul; 13(7):863-70. PubMed ID: 17580265
[TBL] [Abstract][Full Text] [Related]
8. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK; Hong PS; Tutsch K; Trump DL
Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
[TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy.
Joqueviel C; Martino R; Gilard V; Malet-Martino M; Canal P; Niemeyer U
Drug Metab Dispos; 1998 May; 26(5):418-28. PubMed ID: 9571223
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide.
Takamoto S; Sakura N; Namera A; Yashiki M
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 806(1):59-63. PubMed ID: 15149612
[TBL] [Abstract][Full Text] [Related]
13. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
Dulley FL; Vigorito AC; Aranha FJ; Sturaro D; Ruiz MA; Saboya R; Macedo MC; Da Silva RL; Chamone DA; Mehta J; Bacigalupo A; De Souza CA
Bone Marrow Transplant; 2004 Jan; 33(1):9-13. PubMed ID: 14578930
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
[TBL] [Abstract][Full Text] [Related]
17. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.
Boucher M; Meen M; Codron JP; Coudore F; Kemeny JL; Eschalier A
J Urol; 2000 Jul; 164(1):203-8. PubMed ID: 10840460
[TBL] [Abstract][Full Text] [Related]
19. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
